Skip to main content

Table 4 Temporal trends in dossier evidence inclusion and characteristics

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

 

DERP II

DERP III

DERP IV

Proportion of SRs with dossier data

11/21 (52%)

7/10 (70%)

7/9 (78%)

Proportion of total dossier evidence

68/160 (42.5%)

50/160 (31.3%)

42/160 (26.3%)

Studies vs supplemental evidence

 Studies

60

37

26

 Supplemental evidence

8

13

16

Study quality

 Good

4 (6.7%)

1 (2.7%)

4 (15.4%)

 Fair

43 (71.7%)

33 (89.2%)

20 (76.9%)

 Poor

13 (21.7%)

3 (8.1%)

2 (7.7%)